Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
Would you recommend adjuvant chemo-RT for an upper rectal pT3N0 (2/24 nodes with positive isolated tumors cells) s/p LAR and FOLFOX?
Related Questions
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?
How would you manage a patient with de novo oligometastatic anal cancer with a single metastasis in the pubic bone?
Is it safe to treat the stomach to a definitive dose if the patient has a G-tube/PEG in place?
Do the results of recently presented ACCORD trial for EHC and gallbladder cancers have implications for your adjuvant treatment recommendations?
When treating with SBRT and immunotherapy for unresectable HCC, how do you sequence the treatment?
Which GI cancer patients do you use oral contrast in staging CT scans?
In patients with unresectable, liver-limited neuroendocrine tumors (NETs), what clinical or radiographic criteria guide your decision to prioritize systemic therapy over locoregional approaches?
In an N+ rectal adenocarcinoma treated via PROSPECT with neoadjuvant FOLFOX with omission of CRT and no treatment response in the primary on pathology (ypN+), would you offer adjuvant chemotherapy or chemo-radiation?
What adjuvant treatment approach would you recommend for a patient with early-stage MSI-high gastric cancer who received neoadjuvant ipilimumab (×2) and nivolumab (×6) per the NEONIPIGA regimen, followed by R0 resection with no pathologic response?
Would you include the tract in your treatment field in a patient with squamous cell carcinoma of the anal canal presenting with an ano-cutaneous fistula?
